



**Intimate partner violence (IPV) and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000614
Article Type:	Research
Date Submitted by the Author:	15-Nov-2011
Complete List of Authors:	Stene, Lise; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine Dyb, Grete; University of Oslo, The Norwegian Centre for Violence and Traumatic Stress Studies Tverdal, Aage; Norwegian Institute of Public Health, Department of Pharmacoepidemiology Jacobsen, Geir; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine Schei, Berit; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine; St Olavs University Hospital, Department of Obstetrics and Gynaecology
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Public health, Pharmacology & therapeutics, Health services research, Addiction
Keywords:	EPIDEMIOLOGY, PUBLIC HEALTH, SOCIAL MEDICINE, PREVENTIVE MEDICINE, MENTAL HEALTH

SCHOLARONE™  
Manuscripts

15.11.2011

Lise Eilin Stene

1  
2  
3 **Intimate partner violence and prescription of potentially addictive drugs:**  
4 **prospective cohort study of women in the Oslo Health Study**  
5

6 Lise Eilin Stene, Grete Dyb, Aage Tverdal, Geir Wenberg Jacobsen, Berit Schei  
7  
8  
9

10 **Names, institutional affiliations, and addresses of all authors**  
11

12 Lise Eilin Stene

13 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

14 University of Science and Technology,

15 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

16 Telephone: +47 73 59 75 37 / +47 98 04 48 17

17 Fax: +47 73 59 75 77

18 E-mail: lise.e.stene@ntnu.no

19 Profession/Academic degree: MD  
20  
21

22 Grete Dyb

23 The Norwegian Centre for Violence and Traumatic Stress Studies, University of Oslo

24 Address: Kirkeveien 166, building 48, NO-0407 Oslo, Norway

25 E-mail: grete.dyb@nkvts.unirand.no

26 Profession/Academic degree: MD, PhD

27 Preferred degree: PhD  
28  
29

30 Aage Tverdal

31 Department of Pharmacoepidemiology, Norwegian Institute of Public Health

32 Address: P.O.Box 4404, Nydalen, NO-0403 Oslo, Norway

33 E-mail: aage.tverdal@fhi.no

34 Profession/Academic degree: Department Director, PhD

35 Preferred degree: PhD  
36  
37

38 Geir Wenberg Jacobsen

39 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

40 University of Science and Technology

41 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

42 E-mail: geir.jacobsen@ntnu.no

43 Profession/Academic degree: MD, Dr PH

44 Preferred degree: Dr PH  
45  
46

47 Berit Schei

48 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

49 University of Science and Technology / Department of Obstetrics and Gynaecology, St Olavs

50 University Hospital

51 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

52 E-mail: berit.schei@ntnu.no

53 Profession/Academic degree: MD, Professor

54 Preferred degree: Professor  
55  
56  
57

58 **Corresponding author:** Lise Eilin Stene, lise.e.stene@ntnu.no  
59  
60

15.11.2011

Lise Eilin Stene

**Suggested keywords (MeSH terms):**

Spouse abuse; Domestic Violence; Pharmacoepidemiology; Drug and Narcotic Control; Substance-Related Disorders.

**Abstract**

**Objectives:** To investigate the prescription of potentially addictive drugs, including analgesics and CNS depressants, to women exposed to intimate partner violence (IPV).

**Design:** Prospective population based cohort study.

**Setting:** Information about intimate partner violence from the Oslo Health Study 2000/2001 was linked with prescription data from the Norwegian Prescription Database from 1.1.2004 through 31.12.2009.

**Participants:** The study included 6081 women aged 30 to 60 years.

**Main outcome measures:** Prescription rate ratios (RRs) for potentially addictive drugs derived from negative binomial models, adjusted for age, education, paid employment, marital status, chronic musculoskeletal pain, mental distress, and sleep problems.

**Results:** Altogether 819 (13.5%) of 6081 women reported ever experiencing intimate partner violence: 454 (7.5%) comprised physical and/or sexual IPV; 365 (6.0%) psychological IPV alone. Prescription rates for potentially addictive drugs were clearly higher among women exposed to IPV: crude RRs were 3.57 (95% confidence interval 2.89 to 4.40) for physical/sexual IPV and 2.13 (1.69 to 2.69) for psychological IPV alone. After full adjustment RRs were 1.83 (1.50 to 2.22) for physical/sexual IPV, and 1.97 (1.59 to 2.45) for psychological IPV alone. Prescription rates were increased both for potentially addictive analgesics and CNS depressants. Furthermore, women who reported IPV were more likely to receive potentially addictive drugs from multiple physicians.

**Conclusions:** Women exposed to intimate partner violence, including psychological violence alone, more often received prescriptions for potentially addictive drugs. Assessment of IPV exposure may uncover needs for interventions other than prescription drugs.

**Article focus**

- Cross-sectional studies have suggested that intimate partner violence (IPV) is associated with increased medication use in women.
- Although substance abuse is common among women who have experienced IPV, former studies have not addressed the prescription of drugs with addiction potential.
- We assessed the relationship of IPV to prescription rates for potentially addictive drugs, including analgesics and CNS depressants, for women in Oslo, Norway.

**Key messages**

- This longitudinal study showed that women exposed to intimate partner violence, including psychological violence alone, more often received prescriptions for potentially addictive drugs compared to non-exposed women.
- Prescription rates were increased both for potentially addictive analgesics and CNS depressants.
- Women who had experienced IPV more often received prescriptions from multiple physicians.

**Strengths and limitations of this study**

- A major strength is the prospective and accurate measurement of drug prescriptions from a national register. The study is population based, and adds new information about the prescription of restricted drugs with verified addictive potential to women exposed to intimate partner violence.
- Limitations of the study include the low participation rate, and the lack of prescription data between the Oslo Health Study in 2000/2001 until the establishment of the Norwegian Prescription Database in 2004. We had no information if exposure to IPV was assessed in connection with prescription, and cannot evaluate the appropriateness of drug prescription.

15.11.2011

Lise Eilin Stene

**Word count:**

Abstract: 239

Main text: 2895

**Introduction**

Intimate partner violence (IPV) is associated with a broad range of physical and mental health problems in women, including injuries, chronic pain, depression, anxiety, sleep disorders, and substance abuse.<sup>1-4</sup> Cross-sectional studies further indicate that women who have experienced violence from an intimate partner are more likely to use analgesic and psychotropic drugs.<sup>2,5,6</sup> These drugs can be of clinical benefit in treatment of pain, mental distress, and insomnia; however, they do also have several adverse effects. Some of them, such as opioid analgesics and benzodiazepines, may within few weeks of use lead to physical and psychological addiction.<sup>7,8</sup> The development of drug tolerance will additionally result in decreasing effectiveness and increasing dose requirements over time. Due to potential dependence and abuse the authorities have implemented control measures to restrict prescriptions for potentially addictive drugs.<sup>9</sup> Still, the overall prescription has increased during the past decade.<sup>9,10</sup>

There is limited research linking IPV and use of prescription drugs. The current knowledge is primarily based on self-reported drug use from cross-sectional studies.<sup>2,5,6,11</sup> Although substance abuse is common among women who have experienced IPV,<sup>1,12</sup> previous studies have not addressed prescription of drugs with addiction potential. Former research has also mostly been restricted to IPV comprising physical or sexual violence.<sup>3,13</sup> However, recent findings indicate that psychological violence by an intimate partner is common and associated with adverse health outcomes irrespective of whether it is accompanied with physical or sexual violence.<sup>5,14</sup>

15.11.2011

Lise Eilin Stene

1  
2  
3 We did a longitudinal analysis of register-based prescription data from women in Oslo,  
4  
5 Norway. The aim was to assess the prescription rates for potentially addictive drugs, including  
6  
7 analgesics and CNS depressants, to women exposed to physical and/or sexual IPV and  
8  
9 psychological IPV alone.  
10

## 11 12 13 14 **Methods**

### 15 16 *Data sources*

17  
18 Our study sample was a population based cohort of women who participated in the Oslo  
19  
20 Health Study (HUBRO) in 2000/2001. Prescription data were collected from the Norwegian  
21  
22 Prescription Database (NorPD) from its establishment in 1.1.2004 through 31.12.2009. Data  
23  
24 from HUBRO, Statistics Norway and NorPD were merged by use of a unique identification  
25  
26 number which is allocated to all individuals living in Norway.  
27  
28

29  
30  
31 Records from NorPD cover all prescriptions dispensed from Norwegian pharmacies to  
32  
33 individuals treated in ambulatory care.<sup>15</sup> Drugs are classified according to the Anatomical  
34  
35 Therapeutic Chemical (ATC) classification.<sup>16</sup> Data from NorPD include encrypted identifiers  
36  
37 for patients and prescribers, ATC code, defined daily dose (DDD), date of dispensing, and if  
38  
39 applicable reimbursement code. The indication for prescription is not recorded, but the  
40  
41 reimbursement code may in some cases indicate the patient's diagnosis. The DDD determined  
42  
43 by the WHO collaborating centre for drug statistics is the assumed average maintenance dose  
44  
45 per day for a drug used for its main indication in adults.<sup>16</sup> Person-time at risk was calculated  
46  
47 using information on respondents' month/year of death and emigration from Statistics  
48  
49 Norway until 1.1.2006, and month/year of death from NorPD in 2006-2009.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 The Oslo Health Study was conducted under the joint collaboration of the Norwegian Institute  
4 of Public Health, the University of Oslo and the Municipality of Oslo. Details about the  
5 design, the questionnaires and data collection procedures are described previously, and  
6 information is available at the web page of the Norwegian Institute of Public Health.<sup>5,17,18</sup> A  
7 main questionnaire and an invitation to attend a health screening were mailed to all citizens  
8 from selected birth cohorts. Additional questionnaires were distributed at the screening  
9 stations to be answered by the participants at home and returned by mail in a pre-paid  
10 envelope. The HUBRO questionnaires covered sociodemographics, current and past health,  
11 lifestyle, health service utilization, medication use, and life events. The additional  
12 questionnaires also included questions about violence, and were addressed to women born in  
13 1940, 1941, 1955, 1960 and 1970. Totally, 16926 women in these age groups were invited to  
14 participate, of whom 8094 (48%) attended screening. Still, eligibility into our study required  
15 that women had answered at least one question about violence (figure 1). Furthermore,  
16 responders who died or emigrated before 2004 were excluded. Patients with reimbursement  
17 codes for cancer were also excluded since prescription for potentially addictive drugs is less  
18 restricted for them.

### Variables

#### Intimate partner violence

19 The study exposure was lifetime experience of intimate partner violence. Violence was  
20 measured with five questions in HUBRO: (a) “Have you ever been systematically  
21 intimidated, degraded or humiliated over a longer period of time?” (b) “Have you ever  
22 experienced threats to harm you or someone close to you?” (c) “Have you ever been  
23 physically attacked/abused?” (d) “Have you ever been forced into sexual activities?” (e)  
24 “Has anyone ever raped you or tried to rape you?” Response alternatives were “No”, “Yes,  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 below 18 years of age” and “Yes, 18 years or above”. Each question (a)–(e) comprised  
4  
5 separate questions about perpetrator (stranger, family/relative, partner, friend/acquaintance)  
6  
7 and time of exposure (less vs. more than 12 months ago). Violence was defined as intimate  
8  
9 partner violence (IPV) when the respondent reported their partner as perpetrator.

10  
11 Psychological abuse was defined as positive answers to question (a) and/or (b), physical  
12  
13 violence as a positive response to question (c), and sexual violence as answered yes to  
14  
15 question (d) and/or (e). IPV was classified as physical and/or sexual IPV if the woman  
16  
17 answered yes to question c, d and/or e, as psychological IPV alone if she answered no to  
18  
19 question c–e and yes to question a and/or b, and no IPV (reference) if she answered no to all  
20  
21 questions. The category physical and/or sexual IPV may also have included psychological  
22  
23 abuse.  
24  
25  
26  
27  
28

### 29 Prescriptions

30  
31 The main outcome was prescriptions for potentially addictive drugs, including ATC codes  
32  
33 N02A: Opioid analgesics; M03BA02: Carisoprodol; N05BA: Benzodiazepine anxiolytics;  
34  
35 N05CD: Benzodiazepine hypnotics; and N05CF: Benzodiazepine-related hypnotics (z-  
36  
37 hypnotics). Opioid analgesics and the muscle relaxant Carisoprodol were classified as  
38  
39 potentially addictive analgesics; benzodiazepine anxiolytics/hypnotics and z-hypnotics as  
40  
41 CNS depressants. All drugs are classified as restricted by the Norwegian Medicines Agency.<sup>9</sup>  
42  
43  
44  
45  
46

### 47 Other variables

48  
49 Variables from HUBRO covered sociodemographics (age, education, paid employment,  
50  
51 marital status, and country of birth), lifestyle (daily cigarette smoking and alcohol use),  
52  
53 medical history (chronic musculoskeletal pain, mental distress, sleep problems, and use of  
54  
55 potentially addictive drugs) and physical and/or sexual violence from other than partner as  
56  
57  
58  
59  
60



15.11.2011

Lise Eilin Stene

1  
2  
3 child and adult. Mental distress was assessed by the Hopkins Symptoms Checklist-10 (HSCL-  
4  
5 10), which primarily covers symptoms of depression and anxiety during the previous week. It  
6  
7 comprises ten items scored on a scale from 1 (not at all) to 4 (extremely). When three or more  
8  
9 items were missing, mental distress was classified as missing. If one or two items were  
10  
11 missing, they were replaced with the sample mean value for corresponding items. Mean score  
12  
13 served as measure of mental distress, and was dichotomized with cut off at  $\geq 1.85$ . HSCL-10  
14  
15 has displayed high psychometric qualities in population-based studies.<sup>19</sup> Chronic  
16  
17 musculoskeletal pain was defined as pain and/or stiffness in muscles and joints at least 3  
18  
19 months at a stretch last year; sleep problems as troubled by sleeplessness more than once a  
20  
21 week. Use of potentially addictive drugs at baseline was recorded with an open question in  
22  
23 HUBRO about drugs used the previous four weeks. Women who reported trade names of  
24  
25 potentially addictive drugs were defined as users at baseline.  
26  
27  
28  
29  
30

### 31 *Statistical analysis*

32  
33 Crude and multivariable-adjusted prescription rate ratios (RR) were estimated with Poisson  
34  
35 models with number of prescriptions as outcome. Due to overdispersion we used the negative  
36  
37 binomial models. Many women did not receive any medicine, that is a large part with zero  
38  
39 count, and if the Vuong test favoured a zero-inflated negative binomial model we used this.  
40  
41 The women were at risk for medicine prescriptions from January 1, 2004 until  
42  
43 death/emigration or December 31 2009. The logarithm of months of follow-up in Nor PD  
44  
45 was used as offset to allow for differing follow-up duration. The models included a priori  
46  
47 defined covariates: Model 1 adjusted for age, education, paid employment, and marital status,  
48  
49 while model 2 additionally included former chronic musculoskeletal pain, mental distress, and  
50  
51 sleep problems. Analyses were restricted to women with complete data on included variables.  
52  
53  
54  
55 Univariate associations between independent variables and drug use were examined with  
56  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 Pearson  $\chi^2$  tests. All statistical inferences were based on a two-sided significance level of  
4  
5 0.05. Analyses were performed with SPSS 16.0 and STATA 11.1 for Windows.  
6  
7

## 8 9 **Results**

10 The study included 6081 (75.1 %) of 8094 women who attended screening (figure 1).  
11  
12 Altogether 2013 were excluded: 1271 did not return the questionnaires, 352 answered no  
13  
14 questions on violence, 233 declined linkages to NorPD, 60 died or emigrated before 2004, and  
15  
16 97 had prescriptions reimbursed due to cancer. Another 90 (1.5 %) women died or emigrated  
17  
18 during follow-up.  
19  
20  
21  
22  
23

24  
25 Figure 2 shows the distribution of women by type of IPV experiences. Totally, 819 (13.5 %)  
26  
27 women reported ever experiencing any type of IPV: 702 (11.5 %) disclosed psychological  
28  
29 IPV; 369 (6.1 %) physical IPV and 193 (3.2 %) sexual IPV. Among the 454 women who  
30  
31 disclosed physical and/or sexual IPV, 337 (74.2%) also reported psychological IPV.  
32  
33

34 Table 1 displays characteristics of women and experiences of non-partner violence by  
35  
36 exposure category. Both psychological IPV alone and physical/sexual IPV were more  
37  
38 common in women who were middle aged, were divorced/separated, smoked cigarettes,  
39  
40 reported mental distress, and had chronic musculoskeletal pain. Furthermore, childhood and  
41  
42 adult experiences of physical/sexual violence from someone other than their partner were  
43  
44 more frequent among women in the two IPV exposure groups. In addition, women exposed to  
45  
46 physical/sexual IPV more often reported low education, no employment, frequent alcohol use,  
47  
48 and sleep problems.  
49  
50  
51

52  
53  
54 Women who reported IPV were more frequently prescribed potentially addictive drugs; i.e.  
55  
56 analgesics as well as CNS depressants (table 2). The overall mean number of daily defined  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 doses (DDD) was also higher among the group of women who had been exposed to IPV: 513  
4  
5 (95% confidence interval 359 to 667) for sexual/physical IPV; and 255 (175 to 335) for  
6  
7 psychological IPV alone, compared to 144 (127 to 161) among unexposed women.

8  
9 Furthermore, exposed women were more likely to obtain prescriptions for potentially  
10  
11 addictive drugs from multiple ( $\geq 3$ ) physicians.  
12

13  
14  
15  
16 The relationship between exposure to IPV and drug prescriptions were explored further in  
17  
18 negative binomial regression models (table 3). Prescription rates were two times higher for  
19  
20 women who reported psychological IPV alone, and more than three times higher for those  
21  
22 who reported physical/sexual IPV compared to women who did not report IPV. After  
23  
24 adjustment for sociodemographics prescription rates remained twice as high both for  
25  
26 physical/sexual IPV and psychological IPV alone compared to unexposed women (model 1).  
27  
28

29  
30 The association appeared consistent across analgesics and CNS depressants. Additional  
31  
32 adjustments for prior chronic musculoskeletal pain, mental distress, and sleep disorders  
33  
34 sparsely reduced rate ratios (model 2).  
35  
36  
37

38  
39 At baseline (2000/2001) 620 (10.2 %) women reported use of potentially addictive drugs last  
40  
41 4 weeks, of whom 550 (9.0 %) also received prescriptions during follow-up. Drug use was  
42  
43 more common among women who had experienced IPV: 22.9 % for physical and/or sexual  
44  
45 IPV and 14.3 % for psychological IPV alone compared to 8.8 % for unexposed women.  
46  
47 Prescription rates remained significantly higher for exposed women when women who used  
48  
49 drugs at baseline were excluded: After model 2 adjustments prescription rate ratios were 1.38  
50  
51 (1.10 to 1.72) for physical/sexual IPV and 1.55 (1.23 to 1.96) for psychological IPV alone.  
52  
53  
54  
55  
56  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

**Discussion**

Women with lifetime experiences of IPV received prescriptions for potentially addictive drugs two to four times more frequently than unexposed women. The increase applied to both potentially addictive analgesics and CNS depressants, and remained significantly higher after multivariable adjustments.

A major strength of our study is the prospective and accurate measurement of drug prescriptions from a national register.<sup>15</sup> It substantiates previous cross-sectional findings of increased medication use among women exposed to IPV,<sup>5,6,11,14</sup> and adds new evidence about restricted drugs with verified addictive potential. Our sample was enrolled from a large-scale survey with consent to link information to health registers. Loss to follow-up was therefore minor. While many former studies of IPV have recruited participants within health or legal services, the population-based design of the current study enabled inclusion of women regardless of help-seeking. However, the participation rate in HUBRO was low. Individuals who were unmarried, had low socioeconomic status, non-western origin, and received disability pension were underrepresented. Prevalence of IPV may therefore have been underestimated, since IPV was associated with low socioeconomic status and poor health in former studies as well as our.<sup>1-4</sup> Actually, our prevalence estimates were lower compared with a Norwegian national survey of IPV.<sup>2</sup> The latter used a more comprehensive violence questionnaire with a potentially higher sensitivity than the more general questions on violence in HUBRO. Still, a study of potential non-participation bias in HUBRO found largely unbiased association estimates.<sup>17</sup> Some women in the control group may, however, have experienced IPV during follow-up. This would probably bias the estimates toward zero. Another limitation is the lack of prescription data between HUBRO in 2000/2001 until the establishment of NorPD in 2004. Despite the time lag, we cannot certify that IPV exposure

15.11.2011

Lise Eilin Stene

1  
2  
3 preceded drug use. However, prescription rates remained significantly increased when women  
4  
5 who reported use of potentially addictive drugs in HUBRO were excluded from analyses. We  
6  
7 did not assess all potentially addictive drugs; e.g. CNS stimulants were not included since  
8  
9 they were rarely prescribed for women in the eligible age categories.<sup>20</sup>  
10

11  
12  
13  
14 Prescription rates were highest among women who had experienced IPV comprising physical  
15  
16 and/or sexual violence, but were clearly higher for psychological IPV alone as well.  
17  
18 Most of the women who reported physical and/or sexual IPV had experienced multiple types  
19  
20 of violence, including psychological abuse (figure 2). Stronger associations for physical  
21  
22 and/or sexual IPV may therefore represent a cumulative effect. Furthermore, after adjustments  
23  
24 for sociodemographic variables the strengths of the associations were approximately equal  
25  
26 (model 1). Thus, our findings consolidate the emerging evidence of a negative health impact  
27  
28 of psychological IPV irrespective of whether it co-occurs with physical or sexual  
29  
30 violence.<sup>5,14,21</sup> Adjustment for chronic musculoskeletal pain, mental distress and sleep  
31  
32 disorders at baseline sparsely reduced rate differences (model 2). There is generally little  
33  
34 research on predictors for use of potentially addictive drugs. Previously suggested predictors  
35  
36 include gender, age, ethnicity, employment, mental illness, and certain physical diagnosis.<sup>22</sup>  
37  
38 Still, it is uncertain whether some variables should be considered as potential confounders or  
39  
40 intermediate variables on a causal path between IPV and drug prescriptions.<sup>23</sup> Overadjustment  
41  
42 would occur if multivariable analysis included the latter.<sup>24</sup> Our analysis may also have missed  
43  
44 relevant confounders. Nonetheless, we tested several potential sociodemographic and clinical  
45  
46 confounders, yet the associations remained significant. The robust relationship between IPV  
47  
48 and drug prescription underscores the contribution of IPV to the burden on women's health.  
49  
50 Potentially addictive drugs may help to relieve pain, anxiety, and sleep disorders, which are  
51  
52 all associated with IPV.<sup>1-4</sup> The higher prescription frequency among women exposed to IPV  
53  
54  
55  
56  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 may therefore reflect a greater need of symptom-relief. However, such drugs have many  
4  
5 adverse side effects other than addiction, such as impaired psychomotor function, amnesia,  
6  
7 vertigo, sedation, hyperalgesia, constipation, nausea, increased anxiety, and higher risk of  
8  
9 accidents.<sup>7,8</sup> A combination with alcohol is particularly dangerous, and deliberate overdose is  
10  
11 not uncommon. Furthermore, medical use of potentially addictive drugs is associated with  
12  
13 non-medical use.<sup>25</sup> Substance use disorders and suicidal attempts are both associated with  
14  
15 IPV,<sup>1,4,12,26</sup> and should be assessed before such drugs are prescribed.  
16  
17  
18  
19

20  
21 We cannot evaluate the appropriateness of drug prescription or the occurrence of prescription  
22  
23 drug abuse. Yet it may be of concern that women who reported IPV more often acquired their  
24  
25 drugs from multiple physicians. This might be an indicator of prescription drug abuse.<sup>27</sup>  
26

27  
28 Furthermore, former studies have demonstrated that non-clinical factors such as time-saving  
29  
30 and a feeling of inadequacy towards patients in difficult psychosocial situations influenced  
31  
32 physicians' prescription.<sup>28,29</sup> A survey among Norwegian General Practitioners also revealed  
33  
34 that the vast majority had prescribed potentially addictive drugs even though they doubted  
35  
36 their benefit.<sup>30</sup> We had no information if exposure to IPV was assessed among women in our  
37  
38 study in connection with prescription. However, a study of rape survivors showed that the  
39  
40 majority of those who received a prescription for sedatives and/or antidepressants, did so  
41  
42 without disclosing the assault.<sup>31</sup> Moreover, women who received a prescription after they had  
43  
44 told their physician about the rape, often felt troubled by the response. We have not found  
45  
46 similar studies related to IPV, but it has been documented that few physicians identify IPV  
47  
48 exposure.<sup>32</sup>  
49  
50  
51  
52  
53

54 The context of drug prescription and physicians' recognition of IPV among exposed women  
55  
56 should be investigated in future studies. Our study was performed in an urban population of  
57  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 women in Norway, a country with universal health care. External validity may be limited by  
4  
5 differences in how health care provision is organised and financed. Access to prescription  
6  
7 drugs may depend more on personal economic means in countries with a different kinds of  
8  
9 insurance-based health care. It may also vary between urban and rural settings. Moreover, we  
10  
11 did not have any data on IPV exposure among men. Similar studies should be performed in  
12  
13 other countries and in rural settings, and include both genders.  
14  
15

16  
17  
18 Health care providers should be aware that women who have experienced any kind of IPV  
19  
20 more frequently than others receive prescriptions for potentially addictive drugs. Many  
21  
22 physicians unknowingly see and treat women living in violent relationships,<sup>33</sup> thus it becomes  
23  
24 a hidden and chronic health risk. Physicians may use therapeutic relationships to identify  
25  
26 violence, ensure appropriate medical care, and initiate interventions to end violence. It is  
27  
28 therefore essential to develop a comprehensive health service response to detect IPV and its  
29  
30 various health impacts. Assessments of ongoing exposure to violence and the psychological  
31  
32 stress response may disclose needs for interventions other than prescription drugs.  
33  
34  
35  
36  
37  
38

## 39 Notes

### 40 Acknowledgements

41  
42 The data collection was conducted as part of the Oslo Health Study 2000-2001 in  
43  
44 collaboration with the Norwegian Institute of Public Health. We thank all respondents for  
45  
46 participating.  
47  
48  
49  
50  
51  
52

53 **Contributors:** LES contributed to the design of the study, analyzed and interpreted the data,  
54  
55 and wrote the report. GD contributed to the study design and the interpretation of the data. AT  
56  
57 collaborated in the statistical analysis and data management. GWJ contributed to the study  
58  
59  
60

15.11.2011

Lise Eilin Stene

1  
2  
3 design and the interpretation of the data. BS, the principal investigator, conceived the study  
4  
5 and designed the protocol. All authors participated in drafting of the report, and approved the  
6  
7 final version.  
8  
9

10  
11  
12 **Funding:** This study was funded by the Norwegian Research Council (grant number  
13  
14 185755/V50). The funding source had no role in study design, data collection, data analysis,  
15  
16 data interpretation, or writing of the report. The authors of this report are responsible for its  
17  
18 content.  
19  
20

21  
22  
23 **Competing interest statement:** The authors have no competing interests to declare. All  
24  
25 authors have completed the Unified Competing Interest form at  
26  
27 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author).  
28  
29  
30

31  
32  
33 **Ethical approval:** The study was approved by the Regional Committee for Medical Research  
34  
35 Ethics and the Norwegian Data Inspectorate. All participants gave written informed consent.  
36  
37  
38

39  
40 **Data sharing:** No additional data available.  
41  
42  
43

#### 44 **References**

- 45  
46  
47 1 Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002; **359**:  
48 1331-1336.  
49 2 Nerøien AI, Schei B. Partner violence and health: Results from the first national study  
50 on violence against women in Norway. *Scandinavian Journal of Public Health* 2008; **36**: 161-  
51 168.  
52 3 Ellsberg M, Jansen H, Heise L, et al. Intimate partner violence and women's physical  
53 and mental health in the WHO multi-country study on women's health and domestic violence:  
54 an observational study. *Lancet* 2008; **371**: 1165-1172.  
55 4 Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate  
56 partner violence for men and women. *Am J Prev Med* 2002; **23**: 260-268.  
57  
58  
59  
60



15.11.2011


Lise Eilin Stene

- 1  
2  
3 5 Stene LE, Dyb G, Jacobsen GW, et al. Psychotropic drug use among women exposed  
4 to intimate partner violence: A population-based study. *Scand J Public Health* 2010; **38**: 88-  
5 95.  
6 6 Romans SE, Cohen MM, Forte T, et al. Gender and psychotropic medication use: The  
7 role of intimate partner violence. *Prev Med* 2008; **46**: 615-621.  
8 7 Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. *Pain*  
9 *Physician* 2008; **11**: S105-120.  
10 8 Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are  
11 they justified? *Eur Neuropsychopharmacol* 1999; **9 Suppl 6**: S399-405.  
12 9 Rønning M, Berg C, Furu K, et al. The Norwegian Prescription Database 2005–2009:  
13 The Norwegian Institute of Public Health; Report 2010:2.  
14 10 Manchikanti L. National drug control policy and prescription drug abuse: facts and  
15 fallacies. *Pain Physician* 2007; **10**: 399-424.  
16 11 Wuest J, Merritt-Gray M, Lent B, et al. Patterns of medication use among women  
17 survivors of intimate partner violence. *Can J Public Health* 2007; **98**: 460-464.  
18 12 Cole J, Logan TK. Nonmedical Use of Sedative-Hypnotics and Opiates Among Rural  
19 and Urban Women with Protective Orders. *Journal of Addictive Diseases* **29**: 395-409.  
20 13 Plichta SB. Intimate partner violence and physical health consequences: policy and  
21 practice implications. *J Interpers Violence* 2004; **19**: 1296-1323.  
22 14 Yoshihama M, Horrocks J, Kamano S. The role of emotional abuse in intimate partner  
23 violence and health among women in Yokohama, Japan. *Am J Public Health* 2009; **99**: 647-  
24 653.  
25 15 Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) -  
26 new opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008;  
27 **18**: 129-136.  
28 16 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC  
29 classification and DDD assignment 2005. Oslo.  
30 17 Sjøgaard AJ, Selmer R, Bjertness E, et al. The Oslo Health Study: The impact of self-  
31 selection in a large, population-based survey. *Int J Equity Health* 2004; **3**: 3.  
32 18 Sjøgaard AJ, Selmer R. The Oslo Health Study. 2006  
33 <http://www.fhi.no/dav/bbb2a86ad7.doc>  
34 (accessed Sept 12 2011).  
35 19 Strand BH, Dalgard OS, Tambs K, et al. Measuring the mental health status of the  
36 Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5  
37 (SF-36). *Nord J Psychiatr* 2003; **57**: 113-118.  
38 20 Norwegian Institute of Public Health 2011 <http://www.norpd.no/Prevalens.aspx>  
39 (accessed 10.08. 2011).  
40 21 Ludermir AB, Lewis G, Valongueiro SA, et al. Violence against women by their  
41 intimate partner during pregnancy and postnatal depression: a prospective cohort study.  
42 *Lancet* **376**: 903-910.  
43 22 Simoni-Wastila L. The use of abusable prescription drugs: the role of gender. *J*  
44 *Womens Health Gend Based Med* 2000; **9**: 289-297.  
45 23 Brookhart MA, Sturmer T, Glynn RJ, et al. Confounding control in healthcare  
46 database research: challenges and potential approaches. *Med Care* **48**: S114-120.  
47 24 Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment  
48 in epidemiologic studies. *Epidemiology* 2009; **20**: 488-495.  
49 25 Fenton MC, Keyes KM, Martins SS, et al. The Role of a Prescription in Anxiety  
50 Medication Use, Abuse, and Dependence. *Am J Psychiat* **167**: 1247-1253.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


15.11.2011

Lise Eilin Stene

- 1  
2  
3 26 Devries K, Watts C, Yoshihama M, et al. Violence against women is strongly  
4 associated with suicide attempts: Evidence from the WHO multi-country study on women's  
5 health and domestic violence against women. *Soc Sci Med* **73**: 79-86.
- 6 27 Pauly V, Frauger E, Pradel V, et al. Which indicators can public health authorities use  
7 to monitor prescription drug abuse and evaluate the impact of regulatory measures?  
8 Controlling High Dosage Buprenorphine abuse. *Drug Alcohol Depend* **113**: 29-36.
- 9 28 Bjorner T, Laerum E. Factors associated with high prescribing of benzodiazepines and  
10 minor opiates. A survey among general practitioners in Norway. *Scand J Prim Health Care*  
11 2003; **21**: 115-120.
- 12 29 Anthierens S, Habraken H, Petrovic M, et al. The lesser evil? Initiating a  
13 benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives.  
14 *Scand J Prim Health Care* 2007; **25**: 214-219.
- 15 30 Vevatne T, Selbekk AS, Sand R. [Addictive drugs prescription practice among general  
16 practitioners]. *Tidsskr Nor Laegeforen* **130**: 1925-1927.
- 17 31 Sturza ML, Campbell R. An exploratory study of rape survivors' prescription drug use  
18 as a means of coping with sexual assault. *Psychology of Women Quarterly* 2005; **29**: 353-363.
- 19 32 Elliott L, Nerney M, Jones T, et al. Barriers to screening for domestic violence. *J Gen*  
20 *Intern Med* 2002; **17**: 112-116.
- 21 33 Soglin LF, Bauchat J, Soglin DF, et al. Detection of intimate partner violence in a  
22 general medicine practice. *J Interpers Violence* 2009; **24**: 338-348.
- 23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1**  
Flow diagram of the study sample selection.



**Figure 2**

Number and percentage of women ever exposed to intimate partner violence (IPV) by type of violence. Totally 819 (13.5 %) of 6081 women reported ever experiencing any type of IPV. The grey area represents exposure group physical and/or sexual IPV (n=454); the white area psychological IPV alone (n=365).



**Intimate partner violence (IPV) and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000614.R1
Article Type:	Research
Date Submitted by the Author:	08-Feb-2012
Complete List of Authors:	Stene, Lise; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine Dyb, Grete; University of Oslo, The Norwegian Centre for Violence and Traumatic Stress Studies Tverdal, Aage; Norwegian Institute of Public Health, Department of Pharmacoepidemiology Jacobsen, Geir; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine Schei, Berit; Norwegian University of Science and Technology, Department of Public Health and General Practice, Faculty of Medicine; St Olavs University Hospital, Department of Obstetrics and Gynaecology
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Public health, Pharmacology & therapeutics, Health services research, Addiction
Keywords:	EPIDEMIOLOGY, PUBLIC HEALTH, SOCIAL MEDICINE, PREVENTIVE MEDICINE, MENTAL HEALTH

SCHOLARONE™  
Manuscripts

10.02.2012

Lise Eilin Stene

1  
2  
3 **Intimate partner violence and prescription of potentially addictive drugs:**  
4 **prospective cohort study of women in the Oslo Health Study**  
5

6 Lise Eilin Stene, Grete Dyb, Aage Tverdal, Geir Wenberg Jacobsen, Berit Schei  
7  
8  
9

10 **Names, institutional affiliations, and addresses of all authors**  
11

12 Lise Eilin Stene

13 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

14 University of Science and Technology,

15 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

16 Telephone: +47 73 59 75 37 / +47 98 04 48 17

17 Fax: +47 73 59 75 77

18 E-mail: lise.e.stene@ntnu.no

19 Profession/Academic degree: MD  
20  
21

22 Grete Dyb

23 The Norwegian Centre for Violence and Traumatic Stress Studies, University of Oslo

24 Address: Kirkeveien 166, building 48, NO-0407 Oslo, Norway

25 E-mail: grete.dyb@nkvts.unirand.no

26 Profession/Academic degree: MD, PhD

27 Preferred degree: PhD  
28  
29

30 Aage Tverdal

31 Department of Pharmacoepidemiology, Norwegian Institute of Public Health

32 Address: P.O.Box 4404, Nydalen, NO-0403 Oslo, Norway

33 E-mail: aage.tverdal@fhi.no

34 Profession/Academic degree: Department Director, PhD

35 Preferred degree: PhD  
36  
37

38 Geir Wenberg Jacobsen

39 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

40 University of Science and Technology

41 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

42 E-mail: geir.jacobsen@ntnu.no

43 Profession/Academic degree: MD, Dr PH

44 Preferred degree: Dr PH  
45  
46

47 Berit Schei

48 Department of Public Health and General Practice, Faculty of Medicine, Norwegian

49 University of Science and Technology / Department of Obstetrics and Gynaecology, St Olavs

50 University Hospital

51 Address: Håkon Jarls gt. 11, NO-7489 Trondheim, Norway

52 E-mail: berit.schei@ntnu.no

53 Profession/Academic degree: MD, Professor

54 Preferred degree: Professor  
55  
56  
57

58 **Corresponding author:** Lise Eilin Stene, lise.e.stene@ntnu.no  
59  
60

10.02.2012

Lise Eilin Stene

**Suggested keywords (MeSH terms):**

Spouse abuse; Domestic Violence; Pharmacoepidemiology; Drug and Narcotic Control; Substance-Related Disorders.

**Abstract**

**Objectives:** To investigate the prescription of potentially addictive drugs, including analgesics and central nervous system (CNS) depressants, to women who had experienced intimate partner violence (IPV).

**Design:** Prospective population based cohort study.

**Setting:** Information about IPV from the Oslo Health Study 2000/2001 was linked with prescription data from the Norwegian Prescription Database from 1.1.2004 through 31.12.2009.

**Participants:** The study included 6081 women aged 30 to 60 years.

**Main outcome measures:** Prescription rate ratios (RRs) for potentially addictive drugs derived from negative binomial models, adjusted for age, education, paid employment, marital status, chronic musculoskeletal pain, mental distress, and sleep problems.

**Results:** Altogether 819 (13.5%) of 6081 women reported ever experiencing IPV: 454 (7.5%) comprised physical and/or sexual IPV; 365 (6.0%) psychological IPV alone. Prescription rates for potentially addictive drugs were clearly higher among women who had experienced IPV: crude RRs were 3.57 (95% confidence interval 2.89 to 4.40) for physical/sexual IPV and 2.13 (1.69 to 2.69) for psychological IPV alone. After full adjustment RRs were 1.83 (1.50 to 2.22) for physical/sexual IPV, and 1.97 (1.59 to 2.45) for psychological IPV alone. Prescription rates were increased both for potentially addictive analgesics and CNS depressants. Furthermore, women who reported IPV were more likely to receive potentially addictive drugs from multiple physicians.

**Conclusions:** Women who had experienced IPV, including psychological violence alone, more often received prescriptions for potentially addictive drugs. Researchers and clinicians

10.02.2012

Lise Eilin Stene

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

should address the possible adverse health and psychosocial impact of such prescription, and focus on developing evidence based health care for women who have experienced IPV.

For peer review only



10.02.2012

Lise Eilin Stene

**Article focus**

- Cross-sectional studies have suggested that intimate partner violence (IPV) is associated with increased medication use in women.
- Although substance abuse is common among women who have experienced IPV, former studies have not addressed the prescription of drugs with addiction potential.
- We assessed the relationship of IPV to prescription rates for potentially addictive drugs, including analgesics and central nervous system (CNS) depressants, for women in Oslo, Norway.

**Key messages**

- This longitudinal study showed that women who had experienced IPV, including psychological violence alone, more often received prescriptions for potentially addictive drugs compared to other women.
- Prescription rates were increased both for potentially addictive analgesics and CNS depressants.
- Women who had experienced IPV more often received prescriptions from multiple physicians.

**Strengths and limitations of this study**

- A major strength is the prospective and accurate measurement of drug prescriptions from a national register. The study is population based, and adds new information about the prescription of restricted drugs with verified addictive potential to women with experiences of IPV.
- Limitations of the study include the low participation rate, and the lack of prescription data between the Oslo Health Study in 2000/2001 until the establishment of the Norwegian Prescription Database in 2004. We had no information if IPV was assessed in connection with prescription, and cannot evaluate the appropriateness of drug prescription.

10.02.2012

**Word count:**

Abstract: 255

Main text: 3022

**Introduction**

Intimate partner violence (IPV) is associated with a broad range of physical and mental health problems in women, including injuries, chronic pain, depression, anxiety, sleep disorders, and substance abuse.<sup>1-4</sup> Cross-sectional studies further indicate that women who have experienced violence from an intimate partner are more likely to use analgesic and psychotropic drugs.<sup>2,5,6</sup> These drugs can be of clinical benefit in treatment of pain, mental distress, and insomnia; however, they do also have several adverse effects. Some of them, such as opioid analgesics and benzodiazepines, may within few weeks of use lead to physical and psychological addiction.<sup>7,8</sup> The development of drug tolerance will additionally result in decreasing effectiveness and increasing dose requirements over time. Due to potential dependence and abuse the authorities have implemented control measures to restrict prescriptions for potentially addictive drugs.<sup>9</sup> Still, the overall prescription has increased during the past decade.<sup>9,10</sup>

There is limited research linking IPV and use of prescription drugs. The current knowledge is primarily based on self-reported drug use from cross-sectional studies.<sup>2,5,6,11</sup> Although substance abuse is common among women who have experienced IPV,<sup>1,12</sup> previous studies have not addressed prescription of drugs with addiction potential. Former research has also mostly been restricted to IPV comprising physical or sexual violence.<sup>3,13</sup> However, recent findings indicate that psychological violence by an intimate partner is common and associated

10.02.2012

Lise Eilin Stene

1  
2  
3 with adverse health outcomes irrespective of whether it is accompanied with physical or  
4  
5 sexual violence.<sup>5,14</sup>  
6

7 We did a longitudinal analysis of register-based prescription data from women in Oslo,  
8  
9 Norway. The aim was to assess the prescription rates for potentially addictive drugs, including  
10  
11 analgesics and CNS depressants, to women who reported physical and/or sexual IPV and  
12  
13 psychological IPV alone.  
14

## 15 16 17 18 **Methods** 19

### 20 *Data sources* 21

22  
23 Our study sample was a population based cohort of women who participated in the Oslo  
24  
25 Health Study (HUBRO) in 2000/2001. Prescription data were collected from the Norwegian  
26  
27 Prescription Database (NorPD) from its establishment in 1.1.2004 through 31.12.2009. Data  
28  
29 from HUBRO, Statistics Norway and NorPD were merged by use of a unique identification  
30  
31 number which is allocated to all individuals living in Norway.  
32

33  
34  
35  
36 Records from NorPD cover all prescriptions dispensed from Norwegian pharmacies to  
37  
38 individuals treated in ambulatory care.<sup>15</sup> Drugs are classified according to the Anatomical  
39  
40 Therapeutic Chemical (ATC) classification.<sup>16</sup> Data from NorPD include encrypted identifiers  
41  
42 for patients and prescribers, ATC code, defined daily dose (DDD), date of dispensing, and if  
43  
44 applicable reimbursement code. The indication for prescription is not recorded, but the  
45  
46 reimbursement code may in some cases indicate the patient's diagnosis. The DDD determined  
47  
48 by the WHO collaborating centre for drug statistics is the assumed average maintenance dose  
49  
50 per day for a drug used for its main indication in adults.<sup>16</sup> Person-time at risk was calculated  
51  
52 using information on respondents' month/year of death and emigration from Statistics  
53  
54 Norway until 1.1.2006, and month/year of death from NorPD in 2006-2009.  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3  
4  
5 The Oslo Health Study was conducted under the joint collaboration of the Norwegian Institute  
6 of Public Health, the University of Oslo and the Municipality of Oslo. Details about the  
7 design, the questionnaires, the data collection, and consent procedures are described  
8 previously, and information is available at the web page of the Norwegian Institute of Public  
9 Health.<sup>5,17,18</sup> A main questionnaire and an invitation to attend a health screening were mailed  
10 to all citizens from selected birth cohorts. Additional questionnaires were distributed at the  
11 screening stations to be answered by the participants at home and returned by mail in a pre-  
12 paid envelope. The HUBRO questionnaires covered sociodemographics, current and past  
13 health, lifestyle, health service utilization, medication use, and life events. The additional  
14 questionnaires also included questions about violence, and were addressed to women born in  
15 1940, 1941, 1955, 1960 and 1970. Totally, 16926 women in these age groups were invited to  
16 participate, of whom 8094 (48%) attended screening. Still, eligibility into our study required  
17 that women had answered at least one question about violence (figure 1). Furthermore,  
18 responders who died or emigrated before 2004 were excluded. Patients with reimbursement  
19 codes for cancer were also excluded since prescription for potentially addictive drugs is less  
20 restricted for them.

### 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 *Variables*

#### 44 45 Intimate partner violence

46  
47 The study exposure variable was lifetime experiences of IPV. Violence was measured with  
48 five questions in HUBRO: (a) “Have you ever been systematically intimidated, degraded or  
49 humiliated over a longer period of time?” (b) “Have you ever experienced threats to harm  
50 you or someone close to you?” (c) “Have you ever been physically attacked/abused?” (d)  
51 “Have you ever been forced into sexual activities?” (e) “Has anyone ever raped you or tried  
52  
53  
54  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 to rape you?” Response alternatives were “No”, “Yes, below 18 years of age” and “Yes,  
4  
5 18 years or above”. Each question (a)–(e) comprised separate questions about perpetrator  
6  
7 (stranger, family/relative, partner, friend/acquaintance) and time of exposure (less vs. more  
8  
9 than 12 months ago). Violence was defined as IPV when the respondent reported their partner  
10  
11 as perpetrator. Psychological abuse was defined as positive answers to question (a) and/or (b),  
12  
13 physical violence as a positive response to question (c), and sexual violence as answered yes  
14  
15 to question (d) and/or (e). IPV was classified as physical and/or sexual IPV if the woman  
16  
17 answered yes to question c, d and/or e, as psychological IPV alone if she answered no to  
18  
19 question c–e and yes to question a and/or b, and no IPV (reference) if she answered no to all  
20  
21 questions. The category physical and/or sexual IPV may also have included psychological  
22  
23 abuse.  
24  
25  
26  
27  
28

### 29 Prescriptions

31  
32 The main outcome was prescriptions for potentially addictive drugs, including ATC codes  
33  
34 N02A: Opioid analgesics; M03BA02: Carisoprodol; N05BA: Benzodiazepine anxiolytics;  
35  
36 N05CD: Benzodiazepine hypnotics; and N05CF: Benzodiazepine-related hypnotics (z-  
37  
38 hypnotics). Opioid analgesics and the muscle relaxant Carisoprodol were classified as  
39  
40 potentially addictive analgesics; benzodiazepine anxiolytics/hypnotics and z-hypnotics as  
41  
42 central nervous system (CNS) depressants. All drugs are classified as restricted by the  
43  
44 Norwegian Medicines Agency.<sup>9</sup>  
45  
46  
47  
48

### 49 Other variables

51  
52 Variables from HUBRO covered sociodemographics (age, education, paid employment,  
53  
54 marital status, and country of birth), lifestyle (daily cigarette smoking and alcohol use),  
55  
56 medical history (chronic musculoskeletal pain, mental distress, sleep problems, and use of  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 potentially addictive drugs) and physical and/or sexual violence from other than partner as  
4  
5 child and adult. Mental distress was assessed by the Hopkins Symptoms Checklist-10 (HSCL-  
6  
7 10), which primarily covers symptoms of depression and anxiety during the previous week. It  
8  
9 comprises ten items scored on a scale from 1 (not at all) to 4 (extremely). When three or more  
10  
11 items were missing, mental distress was classified as missing. If one or two items were  
12  
13 missing, they were replaced with the sample mean value for corresponding items. Mean score  
14  
15 served as measure of mental distress, and was dichotomized with cut off at  $\geq 1.85$ . HSCL-10  
16  
17 has displayed high psychometric qualities in population-based studies.<sup>19</sup> Chronic  
18  
19 musculoskeletal pain was defined as pain and/or stiffness in muscles and joints at least 3  
20  
21 months at a stretch last year; sleep problems as troubled by sleeplessness more than once a  
22  
23 week. Use of potentially addictive drugs at baseline was recorded with an open question in  
24  
25 HUBRO about drugs used the previous four weeks. Women who reported trade names of  
26  
27 potentially addictive drugs were defined as users at baseline.  
28  
29  
30  
31  
32

### 33 *Statistical analysis*

34  
35 Crude and multivariable-adjusted prescription rate ratios (RR) were estimated with Poisson  
36  
37 models with number of prescriptions as outcome. Due to overdispersion we used the negative  
38  
39 binomial models. Nearly half of the women did not receive any potentially addictive  
40  
41 medicine, that is a large part with zero count, and if the Vuong test favoured a zero-inflated  
42  
43 negative binomial model we used this. The women were at risk for medicine prescriptions  
44  
45 from January 1, 2004 until death/emigration or December 31 2009. The logarithm of months  
46  
47 of follow-up in Nor PD was used as offset to allow for differing follow-up duration. The  
48  
49 models included a priori defined covariates: Model 1 adjusted for age, education, paid  
50  
51 employment, and marital status, while model 2 additionally included former chronic  
52  
53 musculoskeletal pain, mental distress, and sleep problems. Univariate associations between  
54  
55 independent variables and drug use were examined with Pearson  $\chi^2$  tests. Both univariable  $\chi^2$   
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 analyses and multivariable regression analyses were restricted to women with complete data  
4  
5 on included variables. All statistical inferences were based on a two-sided significance level  
6  
7 of 0.05. Analyses were performed with SPSS 16.0 and STATA 11.1 for Windows.  
8  
9

## 10 11 12 **Results**

13  
14 The study included 6081 (75.1 %) of 8094 women who attended screening (figure 1).

15  
16 Altogether 2013 were excluded: 1271 did not return the questionnaires, 352 answered no  
17  
18 questions on violence, 233 declined linkages to NorPD, 60 died or emigrated before 2004, and  
19  
20 97 had prescriptions reimbursed due to cancer. Another 90 (1.5 %) women died or emigrated  
21  
22 during follow-up.  
23  
24

25  
26  
27 Figure 2 shows the distribution of women by type of IPV experiences. Totally, 819 (13.5 %)  
28  
29 women reported ever experiencing any type of IPV: 702 (11.5 %) disclosed psychological  
30  
31 IPV; 369 (6.1 %) physical IPV and 193 (3.2 %) sexual IPV. Among the 454 women who  
32  
33 disclosed physical and/or sexual IPV, 337 (74.2%) also reported psychological IPV.  
34  
35

36  
37 Table 1 displays characteristics of women and experiences of non-partner violence by  
38  
39 exposure category. Both psychological IPV alone and physical/sexual IPV were more  
40  
41 common in women who were middle aged, were divorced/separated, smoked cigarettes,  
42  
43 reported mental distress, and had chronic musculoskeletal pain. Furthermore, childhood and  
44  
45 adult experiences of physical/sexual violence from someone other than their partner were  
46  
47 more frequent among women who reported any IPV. In addition, women who had  
48  
49 experienced physical/sexual IPV more often reported low education, no employment, frequent  
50  
51 alcohol use, and sleep problems.  
52  
53  
54  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 Women who reported IPV were more frequently prescribed potentially addictive drugs; i.e.  
4  
5 analgesics as well as CNS depressants (table 2). The overall mean number of daily defined  
6  
7 doses (DDD) was also higher among the group of women who had experienced IPV: 513  
8  
9 (95% confidence interval 359 to 667) for sexual/physical IPV; and 255 (175 to 335) for  
10  
11 psychological IPV alone, compared to 144 (127 to 161) among other women. Furthermore,  
12  
13 women who reported IPV were more likely to obtain prescriptions for potentially addictive  
14  
15 drugs from multiple ( $\geq 3$ ) physicians.  
16  
17  
18  
19

20  
21 The relationship between experiences of IPV and drug prescriptions were explored further in  
22  
23 negative binomial regression models (table 3). Prescription rates were two times higher for  
24  
25 women who reported psychological IPV alone, and more than three times higher for those  
26  
27 who reported physical/sexual IPV compared to women who did not report IPV. After  
28  
29 adjustment for sociodemographics prescription rates remained twice as high both for  
30  
31 physical/sexual IPV and psychological IPV alone compared to other women (model 1). The  
32  
33 association appeared consistent across analgesics and CNS depressants. Additional  
34  
35 adjustments for prior chronic musculoskeletal pain, mental distress, and sleep disorders  
36  
37 sparsely reduced rate ratios (model 2).  
38  
39  
40  
41  
42

43 At baseline (2000/2001) 620 (10.2 %) women reported use of potentially addictive drugs last  
44  
45 4 weeks, of whom 550 (9.0 %) also received prescriptions during follow-up. Drug use was  
46  
47 more common among women who had experienced IPV: 22.9 % for physical and/or sexual  
48  
49 IPV and 14.3 % for psychological IPV alone compared to 8.8 % for other women.  
50

51  
52 Prescription rates remained significantly higher for women who reported IPV even when  
53  
54 women who used drugs at baseline were excluded: After model 2 adjustments prescription  
55  
56  
57  
58  
59  
60



10.02.2012

Lise Eilin Stene

1  
2  
3 rate ratios were 1.38 (1.10 to 1.72) for physical/sexual IPV and 1.55 (1.23 to 1.96) for  
4  
5 psychological IPV alone.  
6  
7  
8  
9

## 11 Discussion

12  
13  
14 Women with lifetime experiences of IPV received prescriptions for potentially addictive  
15  
16 drugs two to four times more frequently than other women. The increase applied to both  
17  
18 potentially addictive analgesics and CNS depressants, and remained significantly higher after  
19  
20 multivariable adjustments.  
21  
22  
23

24  
25 A major strength of our study is the prospective and accurate measurement of drug  
26  
27 prescriptions from a national register.<sup>15</sup> It substantiates previous cross-sectional findings of  
28  
29 increased medication use among women exposed to IPV,<sup>5,6,11,14</sup> and adds new evidence about  
30  
31 restricted drugs with verified addictive potential. Our sample was enrolled from a large-scale  
32  
33 survey with consent to link information to health registers. Loss to follow-up was therefore  
34  
35 minor. While many former studies of IPV have recruited participants within health or legal  
36  
37 services, the population-based design of the current study enabled inclusion of women  
38  
39 regardless of help-seeking. However, the participation rate in HUBRO was low. Individuals  
40  
41 who were unmarried, had low socioeconomic status, non-western origin, and received  
42  
43 disability pension were underrepresented. Prevalence of IPV may therefore have been  
44  
45 underestimated, since IPV was associated with low socioeconomic status and poor health in  
46  
47 former studies as well as our.<sup>1-4</sup> Actually, our prevalence estimates were lower compared with  
48  
49 a Norwegian national survey of IPV.<sup>2</sup> The latter used a more comprehensive violence  
50  
51 questionnaire with a potentially higher sensitivity than the more general questions on violence  
52  
53 in HUBRO. Still, a study of potential non-participation bias in HUBRO found largely  
54  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 unbiased association estimates.<sup>17</sup> Our estimates of associations between IPV and prescription  
4  
5 of potentially addictive drugs might, however, have been affected by differential selection  
6  
7 bias if the severity of IPV and the magnitude of drug use influenced the likelihood of  
8  
9 participation. Furthermore, some women in the control group may have experienced IPV  
10  
11 during follow-up. This would probably bias the estimates toward zero. Since our study was  
12  
13 limited to women aged 30-60 years at baseline, the estimated association between IPV and  
14  
15 prescription of potentially addictive drugs may not necessarily be valid for women in other  
16  
17 age groups. Another limitation is the lack of prescription data between HUBRO in 2000/2001  
18  
19 until the establishment of NorPD in 2004. Despite the time lag, we cannot certify that IPV  
20  
21 preceded drug use. However, prescription rates remained significantly increased when women  
22  
23 who reported use of potentially addictive drugs in HUBRO were excluded from analyses. We  
24  
25 did not assess all potentially addictive drugs; e.g. CNS stimulants were not included since  
26  
27 they were rarely prescribed for women in the eligible age categories.<sup>20</sup>  
28  
29  
30  
31  
32  
33  
34  
35

36 Prescription rates were highest among women who had experienced IPV comprising physical  
37  
38 and/or sexual violence, but were clearly higher for psychological IPV alone as well.  
39

40 Most of the women who reported physical and/or sexual IPV had experienced multiple types  
41  
42 of violence, including psychological abuse (figure 2). Stronger associations for physical  
43  
44 and/or sexual IPV may therefore represent a cumulative effect. Furthermore, after adjustments  
45  
46 for sociodemographic variables the strengths of the associations were approximately equal  
47  
48 (model 1). Thus, our findings consolidate the emerging evidence of a negative health impact  
49  
50 of psychological IPV irrespective of whether it co-occurs with physical or sexual  
51  
52 violence.<sup>5,14,21</sup> Adjustment for chronic musculoskeletal pain, mental distress and sleep  
53  
54 disorders at baseline sparsely reduced rate differences (model 2). There is generally little  
55  
56 research on predictors for use of potentially addictive drugs. Previously suggested predictors  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 include gender, age, ethnicity, employment, mental illness, and certain physical diagnosis.<sup>22</sup>  
4  
5 Still, it is uncertain whether some variables should be considered as potential confounders or  
6  
7 intermediate variables on a causal path between IPV and drug prescriptions.<sup>23</sup> Overadjustment  
8  
9 would occur if multivariable analysis included intermediate variables.<sup>24</sup> Our analysis may also  
10  
11 have missed relevant confounders. Nonetheless, we tested several potential sociodemographic  
12  
13 and clinical confounders, yet the associations remained significant. The robust relationship  
14  
15 between IPV and drug prescription underscores the contribution of IPV to the burden on  
16  
17 women's health.  
18  
19

20  
21 Potentially addictive drugs may help to relieve pain, anxiety, and sleep disorders, which are  
22  
23 all associated with IPV.<sup>1-4</sup> The higher prescription frequency among women who reported  
24  
25 IPV may therefore reflect a greater need of symptom-relief. However, such drugs have many  
26  
27 adverse side effects other than addiction, such as impaired psychomotor function, amnesia,  
28  
29 vertigo, sedation, hyperalgesia, constipation, nausea, increased anxiety, and higher risk of  
30  
31 accidents.<sup>7,8</sup> A combination with alcohol is particularly dangerous, and deliberate overdose is  
32  
33 not uncommon.<sup>7,8,25</sup> Furthermore, medical use of potentially addictive drugs is associated with  
34  
35 non-medical use.<sup>26</sup> Substance use disorders and suicidal attempts are both associated with  
36  
37 IPV,<sup>1,4,12,27</sup> and should be assessed before such drugs are prescribed.  
38  
39  
40  
41  
42

43 We cannot evaluate the appropriateness of drug prescription or the occurrence of prescription  
44  
45 drug abuse. Yet it may be of concern that women who reported IPV more often acquired their  
46  
47 drugs from multiple physicians. This might be an indicator of prescription drug abuse.<sup>28</sup>  
48

49 Furthermore, former studies have demonstrated that non-clinical factors such as time-saving  
50  
51 and a feeling of inadequacy towards patients in difficult psychosocial situations influenced  
52  
53 physicians' prescription.<sup>29,30</sup> A survey among Norwegian General Practitioners also revealed  
54  
55 that the vast majority had prescribed potentially addictive drugs even though they doubted  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 their benefit.<sup>31</sup> We had no information if IPV was assessed among women in our study in  
4  
5 connection with prescription. However, a study of rape survivors showed that the majority of  
6  
7 those who received a prescription for sedatives and/or antidepressants, did so without  
8  
9 disclosing the assault.<sup>32</sup> Moreover, women who received a prescription after they had told  
10  
11 their physician about the rape, often felt troubled by the response. We have not found similar  
12  
13 studies related to IPV, but it has been documented that few physicians identify IPV  
14  
15 experiences.<sup>33</sup>  
16  
17  
18  
19

20  
21 The context of drug prescription and physicians' recognition of IPV among women who have  
22  
23 experienced IPV should be investigated in future studies. Our study was performed in an  
24  
25 urban population of women in Norway, a country with universal health care. External validity  
26  
27 may be limited by differences in how health care provision is organised and financed. Access  
28  
29 to prescription drugs may depend more on personal economic means in countries with a  
30  
31 different kinds of insurance-based health care. It may also vary between urban and rural  
32  
33 settings. Moreover, we did not have any data on IPV experiences among men. Similar studies  
34  
35 should be performed in other countries and in rural settings, and include both genders.  
36  
37  
38  
39

40  
41 There is still a lack of evidence on favorable health service interventions to prevent IPV and  
42  
43 its associated adverse health outcomes.<sup>34,35</sup> However, recent findings indicate that a training  
44  
45 and support programme for professionals in primary care may improve identification and  
46  
47 access to help services of women who experience IPV.<sup>36</sup> Physicians may use therapeutic  
48  
49 relationships to identify violence, ensure appropriate medical care, and initiate interventions  
50  
51 to end violence. Yet many physicians unknowingly see and treat women living in violent  
52  
53 relationships,<sup>37</sup> thus it becomes a hidden and chronic health risk. Health care providers should  
54  
55 be aware that women who have experienced any kind of IPV more frequently than others  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 receive prescriptions for potentially addictive drugs. Researchers and clinicians should  
4  
5 increase the awareness of the health consequences and psychosocial impact of such  
6  
7 prescription, and focus on establishing evidence based health care interventions for women  
8  
9 who have experienced IPV.  
10

## 11 12 13 14 15 16 17 **Notes**

### 18 19 20 **Acknowledgements**

21  
22 The data collection was conducted as part of the Oslo Health Study 2000-2001 in  
23  
24 collaboration with the Norwegian Institute of Public Health. We thank all respondents for  
25  
26 participating.  
27  
28  
29  
30

31 **Contributors:** LES contributed to the design of the study, analyzed and interpreted the data,  
32  
33 and wrote the report. GD contributed to the study design and the interpretation of the data. AT  
34  
35 collaborated in the statistical analysis and data management. GWJ contributed to the study  
36  
37 design and the interpretation of the data. BS, the principal investigator, conceived the study  
38  
39 and designed the protocol. All authors participated in drafting of the report, and approved the  
40  
41 final version.  
42  
43  
44  
45  
46

47 **Funding:** This study was funded by the Norwegian Research Council (grant number  
48  
49 185755/V50). The funding source had no role in study design, data collection, data analysis,  
50  
51 data interpretation, or writing of the report. The authors of this report are responsible for its  
52  
53 content.  
54  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 **Competing interest statement:** The authors have no competing interests to declare. All  
4  
5 authors have completed the Unified Competing Interest form at  
6  
7 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author).  
8  
9

10  
11  
12 **Ethical approval:** The study was approved by the Regional Committee for Medical Research  
13  
14 Ethics and the Norwegian Data Inspectorate. All participants gave written informed consent.  
15  
16

17  
18  
19 **Data sharing:** No additional data available.  
20  
21

## 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

- 1 Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002; **359**: 1331-1336.
- 2 Nerøien AI, Schei B. Partner violence and health: Results from the first national study on violence against women in Norway. *Scandinavian Journal of Public Health* 2008; **36**: 161-168.
- 3 Ellsberg M, Jansen H, Heise L, et al. Intimate partner violence and women's physical and mental health in the WHO multi-country study on women's health and domestic violence: an observational study. *Lancet* 2008; **371**: 1165-1172.
- 4 Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for men and women. *Am J Prev Med* 2002; **23**: 260-268.
- 5 Stene LE, Dyb G, Jacobsen GW, et al. Psychotropic drug use among women exposed to intimate partner violence: A population-based study. *Scand J Public Health* 2010; **38**: 88-95.
- 6 Romans SE, Cohen MM, Forte T, et al. Gender and psychotropic medication use: The role of intimate partner violence. *Prev Med* 2008; **46**: 615-621.
- 7 Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. *Pain Physician* 2008; **11**: S105-120.
- 8 Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? *Eur Neuropsychopharmacol* 1999; **9 Suppl 6**: S399-405.
- 9 Rønning M, Berg C, Furu K, et al. The Norwegian Prescription Database 2005–2009: The Norwegian Institute of Public Health; Report 2010:2.
- 10 Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. *Pain Physician* 2007; **10**: 399-424.
- 11 Wuest J, Merritt-Gray M, Lent B, et al. Patterns of medication use among women survivors of intimate partner violence. *Can J Public Health* 2007; **98**: 460-464.
- 12 Cole J, Logan TK. Nonmedical Use of Sedative-Hypnotics and Opiates Among Rural and Urban Women with Protective Orders. *Journal of Addictive Diseases* **29**: 395-409.
- 13 Plichta SB. Intimate partner violence and physical health consequences: policy and practice implications. *J Interpers Violence* 2004; **19**: 1296-1323.

10.02.2012

Lise Eilin Stene

- 1  
2  
3 14 Yoshihama M, Horrocks J, Kamano S. The role of emotional abuse in intimate partner  
4 violence and health among women in Yokohama, Japan. *Am J Public Health* 2009; **99**: 647-  
5 653.
- 6 15 Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) -  
7 new opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008;  
8 **18**: 129-136.
- 9 16 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC  
10 classification and DDD assignment 2005. Oslo.
- 11 17 Sjøgaard AJ, Selmer R, Bjertness E, et al. The Oslo Health Study: The impact of self-  
12 selection in a large, population-based survey. *Int J Equity Health* 2004; **3**: 3.
- 13 18 Sjøgaard AJ, Selmer R. The Oslo Health Study. 2006  
14 <http://www.fhi.no/dav/bbb2a86ad7.doc> (accessed Sept 12 2011).
- 15 19 Strand BH, Dalgard OS, Tambs K, et al. Measuring the mental health status of the  
16 Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5  
17 (SF-36). *Nord J Psychiatr* 2003; **57**: 113-118.
- 18 20 Norwegian Institute of Public Health 2011 <http://www.norpd.no/Prevalens.aspx>  
19 (accessed 10.08. 2011).
- 20 21 Ludermir AB, Lewis G, Valongueiro SA, et al. Violence against women by their  
21 intimate partner during pregnancy and postnatal depression: a prospective cohort study.  
22 *Lancet* **376**: 903-910.
- 23 22 Simoni-Wastila L. The use of abusable prescription drugs: the role of gender. *J*  
24 *Womens Health Gend Based Med* 2000; **9**: 289-297.
- 25 23 Brookhart MA, Sturmer T, Glynn RJ, et al. Confounding control in healthcare  
26 database research: challenges and potential approaches. *Med Care* **48**: S114-120.
- 27 24 Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment  
28 in epidemiologic studies. *Epidemiology* 2009; **20**: 488-495.
- 29 25 Prescott K, Stratton R, Freyer A, et al. Detailed analyses of self-poisoning episodes  
30 presenting to a large regional teaching hospital in the UK. *Br J Clin Pharmacol* 2009; **68**:  
31 260-268.
- 32 26 Fenton MC, Keyes KM, Martins SS, et al. The Role of a Prescription in Anxiety  
33 Medication Use, Abuse, and Dependence. *Am J Psychiat* **167**: 1247-1253.
- 34 27 Devries K, Watts C, Yoshihama M, et al. Violence against women is strongly  
35 associated with suicide attempts: Evidence from the WHO multi-country study on women's  
36 health and domestic violence against women. *Soc Sci Med* **73**: 79-86.
- 37 28 Pauly V, Frauger E, Pradel V, et al. Which indicators can public health authorities use  
38 to monitor prescription drug abuse and evaluate the impact of regulatory measures?  
39 Controlling High Dosage Buprenorphine abuse. *Drug Alcohol Depend* **113**: 29-36.
- 40 29 Bjorner T, Laerum E. Factors associated with high prescribing of benzodiazepines and  
41 minor opiates. A survey among general practitioners in Norway. *Scand J Prim Health Care*  
42 2003; **21**: 115-120.
- 43 30 Anthierens S, Habraken H, Petrovic M, et al. The lesser evil? Initiating a  
44 benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives.  
45 *Scand J Prim Health Care* 2007; **25**: 214-219.
- 46 31 Veatne T, Selbekk AS, Sand R. [Addictive drugs prescription practice among general  
47 practitioners]. *Tidsskr Nor Laegeforen* **130**: 1925-1927.
- 48 32 Sturza ML, Campbell R. An exploratory study of rape survivors' prescription drug use  
49 as a means of coping with sexual assault. *Psychology of Women Quarterly* 2005; **29**: 353-363.
- 50 33 Elliott L, Nerney M, Jones T, et al. Barriers to screening for domestic violence. *J Gen*  
51 *Intern Med* 2002; **17**: 112-116.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

10.02.2012

Lise Eilin Stene

1  
2  
3 34 Wathen CN, MacMillan HL. Interventions for violence against women: scientific  
4 review. *JAMA* 2003; **289**: 589-600.


5 35 MacMillan HL, Wathen CN, Jamieson E, et al. Screening for intimate partner  
6 violence in health care settings: a randomized trial. *JAMA* 2009; **302**: 493-501.

7 36 Feder G, Davies RA, Baird K, et al. Identification and Referral to Improve Safety  
8 (IRIS) of women experiencing domestic violence with a primary care training and support  
9 programme: a cluster randomised controlled trial. *Lancet* **378**: 1788-1795.

10 37 Soglin LF, Bauchat J, Soglin DF, et al. Detection of intimate partner violence in a  
11 general medicine practice. *J Interpers Violence* 2009; **24**: 338-348.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


For peer review only





**Figure 1**  
Flow diagram of the study sample selection.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 2**

Number and percentage of women who reported intimate partner violence (IPV) by type of violence. Totally 819 (13.5 %) of 6081 women reported ever experiencing any type of IPV. The grey area represents physical and/or sexual IPV (n=454); the white area psychological IPV alone (n=365).

Slettet: ever exposed to

Slettet: exposure group

**Table 1**

Women's sociodemographic, lifestyle and health characteristics, and experiences of non-partner violence by lifetime experiences of intimate partner violence (IPV) at enrollment, 2000/2001.

Characteristics	No IPV (n=5262)		Psychological IPV alone (n=365)		Physical/sexual IPV (n=454)		p value*
	n	(%)	n	(%)	n	(%)	
<b>Age, n=6081</b>							<0.001
30	1530	(29.1)	93	(25.5)	83	(18.3)	
40/45	2231	(42.4)	191	(52.3)	260	(57.3)	
59/60	1501	(28.5)	81	(22.2)	111	(24.4)	
<b>Education level, n=6032</b>							<0.001
Less than upper secondary	745	(14.3)	65	(18.0)	95	(21.1)	
Upper secondary	1579	(30.3)	105	(29.0)	172	(38.1)	
College/University	2895	(55.5)	192	(53.0)	184	(40.8)	
<b>Paid employment, n=6030</b>							<0.001
Yes	4425	(84.8)	303	(83.9)	337	(75.1)	
No	795	(15.2)	58	(16.1)	112	(24.9)	
<b>Marital status, n=6080</b>							<0.001
Unmarried	1866	(35.5)	123	(33.8)	127	(28.0)	
Married	2604	(49.5)	94	(25.8)	146	(32.2)	
Divorced/separated	631	(12.0)	143	(39.3)	172	(37.9)	
Widowed	161	(3.1)	4	(1.1)	9	(2.0)	
<b>Country of birth, n=5620</b>							0.358
Norway	4185	(85.9)	292	(88.5)	365	(87.1)	
Other	686	(14.1)	38	(11.5)	54	(12.9)	
<b>Daily cigarette smoking, n=6032</b>							<0.001
Yes	1334	(25.6)	157	(43.3)	211	(46.6)	
No	3882	(74.4)	206	(56.7)	242	(53.4)	
<b>Alcohol use, n=6046</b>							0.040
4-7 times a week	259	(5.0)	23	(6.3)	34	(7.5)	
Less	4970	(95.0)	341	(93.7)	419	(92.5)	
<b>Chronic musculoskeletal pain, n=5891</b>							<0.001
Yes	1855	(36.4)	156	(43.9)	217	(49.2)	
No	3240	(63.6)	199	(56.1)	224	(50.8)	
<b>Mental distress, n=5809</b>							<0.001
Yes	521	(10.4)	73	(21.2)	117	(27.0)	
No	4510	(89.6)	271	(78.8)	317	(73.0)	
<b>Sleep problems, n=6024</b>							<0.001
>1 weekly	579	(11.1)	48	(13.3)	95	(21.0)	
1≤ weekly	4630	(88.9)	314	(86.7)	358	(79.0)	
<b>Childhood abuse<sup>†</sup>, n=6081</b>							<0.001
Yes	462	(8.8)	65	(17.8)	104	(22.9)	
No	4800	(91.2)	300	(82.2)	350	(77.1)	
<b>Other adult abuse<sup>†</sup>, n=6081</b>							<0.001
Yes	371	(7.1)	79	(21.6)	114	(25.1)	
No	4891	(92.9)	286	(78.4)	340	(74.9)	

<sup>†</sup>Physical and/or sexual violence by other than intimate partner

\*Test of equality across the three categories of IPV experiences

**Table 2**

Prescriptions for potentially addictive drugs by lifetime experiences of intimate partner violence (IPV), 2004-2009.

Prescriptions	No IPV (n=5262)		Psychological IPV alone (n=365)		Physical/sexual IPV (n=454)		p value*
	n	(%)	n	(%)	n	(%)	
<b>Potentially addictive drugs overall</b>							
Any	2767	(52.6)	218	(59.7)	308	(67.8)	<0.001
Frequent <sup>†</sup>	224	(4.3)	30	(8.2)	59	(13.0)	<0.001
<b>Potentially addictive analgesics</b>							
Any	2088	(39.7)	169	(46.3)	227	(50.0)	<0.001
Frequent <sup>†</sup>	244	(4.6)	28	(7.7)	60	(13.2)	<0.001
<b>CNS depressants</b>							
Any	1600	(30.4)	137	(37.5)	223	(49.1)	<0.001
Frequent <sup>†</sup>	224	(4.3)	30	(8.2)	64	(14.1)	<0.001
<b>Multiple prescribers (≥3)<sup>‡</sup></b>	791	(15.0)	81	(22.2)	133	(29.3)	<0.001

<sup>†</sup>Number of prescriptions ≥ 95-percentile of the study sample (potentially addictive drugs overall: ≥27 prescriptions; potentially addictive analgesics: ≥8 prescriptions; CNS depressants: ≥18 prescriptions).

<sup>‡</sup>Total number of women who received prescriptions for potentially addictive drugs from three or more physicians.

\*Test of equality across the three categories of IPV experiences.

**Table 3**

Relationship between lifetime experiences of intimate partner violence (IPV) and prescriptions for potentially addictive drugs, 2004-2009.

	No adjustments, n=6081				Model 1, n=5981 <sup>†</sup>				Model 2, n=5558/5813/5694 <sup>‡</sup>			
	Prescriptions	Person-years	RR	(95% CI)	Prescriptions	Person-years	RR	(95% CI)	Prescriptions	Person-years	RR	(95% CI)
<b>Potentially addictive drugs overall</b>												
No IPV (ref.)	26118	31332	1	-	25714	30828	1	-	23190	28650	1	-
Psychological IPV alone	3788	2166	2.13	(1.69 to 2.69)	3758	2118	2.03	(1.63 to 2.53)	3644	1956	1.97	(1.59 to 2.45)
Physical/sexual IPV	7896	2692	3.57	(2.89 to 4.40)	7802	2644	2.44	(2.00 to 2.97)	7270	2471	1.83	(1.50 to 2.22)
<b>Potentially addictive analgesics</b>												
No IPV (ref.)	11603	31332	1	-	11430	30828	1	-	11009	29945	1	-
Psychological IPV alone	1867	2166	2.37	(1.83 to 3.07)	1862	2118	2.06	(1.61 to 2.64)	1861	2070	2.10	(1.65 to 2.68)
Physical/sexual IPV	3083	2692	3.11	(2.46 to 3.93)	3034	2643	2.04	(1.64 to 2.55)	2910	2572	1.92	(1.55 to 2.39)
<b>CNS depressants</b>												
No IPV (ref.)	14515	31332	1	-	14284	30828	1	-	13194	29358	1	-
Psychological IPV alone	1921	2166	1.94	(1.41 to 2.67)	1896	2118	2.11	(1.56 to 2.85)	1835	1998	1.94	(1.44 to 2.61)
Physical/sexual IPV	4813	2692	3.93	(2.95 to 5.23)	4768	2643	2.83	(2.16 to 3.70)	4534	2537	2.00	(1.53 to 2.61)

<sup>†</sup>Rate ratios (RR) and confidence intervals (CI) adjusted for age, education, employment, and marital status.<sup>‡</sup>Rate ratios (RR) and confidence intervals (CI) adjusted for age, education, employment, marital status, and former symptoms (potentially addictive drugs overall, n=5558: adjusted for chronic musculoskeletal pain, mental distress, and sleep problems; potentially addictive analgesics, n=5813: adjusted for chronic musculo-skeletal pain; CNS depressants, n=5694: adjusted for mental distress and sleep problems).